glp-1 and synthroid for Weight Loss Diabetes Emerging Frontiers in GLP-1 Therapeutics:

The trial reported a 26% reduction in the risk of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke

( Epub 2018/02/24 )

although Semaglutide is now also available as an oral medication ( Heloderma suspectum , has an increased binding affinity to the GLP-1 receptor (GLP-1R) and reduced rate of degradation by DPP-4 compared to GLP-1, increasing its half-life from 1 min to over 2 h ( Three classes of DPP-4 inhibitors (Gliptins) are in clinical use to augment the endogenous incretin effect, and these provide 80%90% efficacy in inhibiting the peptidase

So, broader coverage in 2025 could be more likely